Table 2 Clinical and laboratory features of myeloproliferative neoplasm (MPN) patients used for immunohistochemistry (IHC)

Patients

12

10

13

Gender (M/F)

6/12

2/8

7/6

Age at diagnosis^a

66 (37–72)

55 (33–77)

44 (25–62)

Splenomegaly at diagnosis

2/12

5/10

1/13

Hepatomegaly at diagnosis

2/12

2/10

1/13

Hemoglobin (g/100 mL) at diagnosis^a

20.05 (17.5-22.5)

15.2 (12.7-16.2)

14.15 (12.1-16.3)

Hematocrit at diagnosis^a

58 (51.1-66.4)

45.2 (38.3-48.3)

41.15 (35.6-48.9)

WBC (x10⁹/L) at diagnosis^a

11.1 (5.91-14.7)

8.125 (5.96-11.4)

11.6 (5.24-15.3)

Platelets (x10⁹/L) at diagnosis^a

436.5 (305–1328)

680 (551–1210)

875 (514–3500)

Increased LDH at diagnosis

4/12

0/10

2/13

Thrombotic events at diagnosis

2/12

1/10

2/13

Hemorrhagic events at diagnosis

0/12

0/10

0/13

Thrombotic events after diagnosis

1/12

1/10

2/13

Hemorrhagic events after diagnosis

1/12

0/10

1/13

Disease duration (in months)

87 (24–138)

148.5 (46–333)

87 (0–256)

Treatment duration (in months)^a

83 (0–138)

108 (0–330)

87 (0–256)

Response to treatment

8/12

8/10

8/13